Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity

  1. Michael Asamoah-Boaheng
  2. David Goldfarb
  3. Martin A Prusinkiewicz
  4. Liam Golding
  5. Mohammad E Karim
  6. Vilte Barakauskas
  7. Nechelle Wall
  8. Agatha N Jassem
  9. Ana Citlali Marquez
  10. Chris MacDonald
  11. Sheila F O’Brien
  12. Pascal Lavoie
  13. Brian Grunau

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.7759/cureus.34465
  2. ScreenIT

    SciScore for 10.1101/2022.03.01.482592: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Ethicsnot detected.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    We excluded those with evidence of previous COVID-19 (defined as a positive NAAT COVID-19 test or presence of anti-nucleocapsid antibodies in the blood [Roche, IND, USA] 7) given the known differential impact on antibody responses post-vaccination.
    anti-nucleocapsid
    suggested: None
    6, 9 Serological Testing: All samples were tested with: (1) the Roche Nucleocapsid Elecsys Anti-SARS-Cov-2 (Roche, IND, USA) assay (to confirm eligibility); (2) the quantitative Roche Spike Elecsys Anti-SARS-Cov-2 S assay (Roche, IND, USA), which measures spike total antibody concentrations; (3) the V-PLEX COVID-19 Coronavirus Panel 2 IgG assay (Meso Scale discovery, MD, USA), which measures IgG to the SARS-CoV-2 spike and receptor binding domain (RBD) antigens; and (4) the V-PLEX SARS-CoV-2 Panel 19 ACE2 Kit (Meso Scale Discovery, MD, USA), which measures inhibition of angiotensin-converting enzyme 2 (ACE-2) binding to multiple delta (B.1.617.2) variant spike proteins.
    Anti-SARS-Cov-2
    suggested: None
    ACE2
    suggested: None
    Secondary outcomes included: spike and RBD IgG antibody concentrations (measured with the V-PLEX assay), and inhibition of angiotensin-converting enzyme 2 (ACE-2) binding to wild-type spike protein and several different Delta (B.1.617.2) variant spike proteins (AY.1, AY.2, B.1.617.2/AY.3/AY.5/AY.6/AY.7/AY.14, B.1.617.2/AY.4, and AY.12).
    RBD IgG
    suggested: None
    Software and Algorithms
    SentencesResources
    Statistical analysis: We performed statistical analyses with SPSS (IBM, USA) and R (V. 3.6.1) software.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.03.01.482592v1 on bioRxiv